Dellon Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 11-07-2024
- Paid Up Capital ₹ 0.10 M
as on 11-07-2024
- Company Age 10 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2017)
- Profit 770.44%
(FY 2017)
- Ebitda 1377.08%
(FY 2017)
- Net Worth 810.57%
(FY 2017)
- Total Assets 523.21%
(FY 2017)
About Dellon Pharmaceuticals
The Corporate was formerly known as Dallon Pharmaceuticals Private Limited. The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Mohammad Lari, Jaiprakash Kushwaha, Syed Ahmad, and Two other members serve as directors at the Company.
- CIN/LLPIN
U51397UP2014PTC061784
- Company No.
061784
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Jan 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Gorakhpur, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Dellon Pharmaceuticals Private Limited offer?
Dellon Pharmaceuticals Private Limited offers a wide range of products and services, including Beauty Soap, Skin Whitening Soap, Amoxicillin drugs, Amoxicillin Potassium Clavulanate Tablet.
Who are the key members and board of directors at Dellon Pharmaceuticals?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mohammad Lari  | Director | 07-Jan-2014 | Current |
| Jaiprakash Kushwaha | Director | 07-Jan-2014 | Current |
| Syed Ahmad | Director | 07-Jan-2014 | Current |
| Manish Pandey | Director | 07-Jan-2014 | Current |
| Parminder Singh | Director | 07-Jan-2014 | Current |
Financial Performance of Dellon Pharmaceuticals.
Dellon Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 770.44% increase in profit. The company's net worth Soared by an impressive increase of 810.57%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dellon Pharmaceuticals?
In 2017, Dellon Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Tuffail (India) Pharmaceuticals Private LimitedActive 4 years 2 months
Syed Ahmad is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dellon Pharmaceuticals?
Unlock and access historical data on people associated with Dellon Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dellon Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dellon Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
